Iso-Osmolar Iodixanol Induces Less Increase in Circulating Endothelial Microparticles In Vivo and Less Endothelial Apoptosis In Vitro Compared with Low-Osmolar Iohexol

There is no consensus on whether iodixanol is superior to iohexol. Tis study aimed to compare the efects of iodixanol and iohexol on circulating endothelial microparticles (EMPs) in stable coronary artery disease (CAD) patients with diabetes mellitus (DM), and also their cytotoxic efects on human umbilical vein endothelial cells (HUVECs) in vitro. Methods. 100 CAD patients with DM were randomly assigned to receive iso-osmolar contrast medium iodixanol (group I) or low-osmolar iohexol (group II) during coronary angioplasty. An additional 49 CAD patients without DM receiving iohexol were recruited as group III. Circulating CD31+/CD41a− EMPs, CD62E+ EMPs, and CD31+/CD41a+ platelet microparticles (PMPs) were determined by fow cytometry. In vitro, the cytotoxic efects of iodixanol and iohexol on HUVECs were determined. Results. Circulating CD31+/CD41a− EMPs and PMPs were signifcantly increased afer angioplasty in all 3 groups, while CD62E+ EMPs signifcantly decreased in group I. CD31+/CD41a− EMPs and PMPs were signifcantly higher in group II than group I or III. In vitro, both contrast media induced EMP release and inhibited the viability and induced apoptosis of HUVECs, as well as increasing Bax and cleaved caspase-3 and decreasing Bcl-2. The above efects were less evident in iodixanol than in iohexol. Conclusions. Compared with iohexol, iodixanol induces less release of EMPs in both CAD patients with DM during angioplasty and in vitro HUVEC culture, which is associated with less pronounced proapoptotic efects of iodixanol on HUVECs. Clinical Study Registration Number. Tis study is registered with ChiCTR-TRC-14005183.